Leah Kuntz

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.

After facing challenges, Biogen is discontinuing development and sales of aducanumab (Aduhelm) and focusing on lecanemab (Leqembi).

According to the National Community Pharmacists Association, 97% of independent pharmacy owners reported shortages of Adderall in early 2023.

A new report recommended that ketamine therapy be used only in combination with psychotherapy under the supervision of a clinician.

Data from two phase 3 studies showed that brexpiprazole 2 mg or 3 mg doses significantly improved symptoms of agitation in patients with AAD.

How can current Alzheimer disease treatments be used to best treat patients living with the disease?

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

We may be one step closer to nonprescription naloxone.

ADHD is an all-day affair, and treating it in an adult population can be difficult.

Recent research determined the psychostimulants modafinil, atomoxetine, and guanfacine negatively impact bones.

The National Commission on Correctional Health Care and 166 other national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine.

What are the long term psychiatric and neuropsychiatric complications of COVID-19?

Alzheimer disease psychosis treatment pimavanserin receives Complete Response Letter from the FDA.

Positive results from the phase 3 trial of AD04 show a 79% reduction in heavy drinking.

Axsome Therapeutics announced the robust antidepressant efficacy demonstrated in this latest study.

Home environments have a clear impact on depression treatment outcomes.

A recent study found a negative association between children with ADHD and health eating patterns.

The new drug treats acute agitation associated with schizophrenia, bipolar I, or bipolar II in adults.

According to research examining sexual minority patients, depression can be a consequence of health and behavioral disparities.

Catch up on all the latest in ADHD from the virtual APSARD 2022 Annual Meeting.

Zuranolone treatment in patients with major depressive disorder demonstrates a rapid and statistically significant reduction in depressive symptoms.

A coalition of 240 organizations came together to urge Congress to pass legislation to fight the opioid crisis.

The FDA has approved Dyanavel XR, extended release once-daily tablets for the treatment of attention-deficit/hyperactivity disorder.

A vaccine that prevents oxycodone from entering the brain? This might be the safe, long-lasting, cost-effective solution for opioid use disorders.

The American Medical Association is urging policymakers to act now to prevent further opioid overdose deaths.